Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.33 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1528792 | 1.00 | ALOX15 (0.33) | ALOX15RECQLTSHRTAS2R38BCAT1 | |
| SCHEMBL31231602 | 1.00 | ALOX15 (0.33) | ALOX15RECQLTSHRTAS2R38BCAT1 | |
| SCHEMBL563340 | 1.00 | ALOX15 (0.33) | ALOX15RECQLTSHRTAS2R38BCAT1 | |
| SCHEMBL14556333 | 1.00 | ALOX15 (0.33) | ALOX15RECQLTSHRTAS2R38BCAT1 | |
| Hydrochloric Acid SCHEMBL3065209 | 0.96 | ALOX15 (0.32) | ALOX15RECQLTSHRTAS2R38 | |
| Hydrochloric Acid SCHEMBL3597570 | 0.96 | ALOX15 (0.32) | ALOX15RECQLTSHRTAS2R38 | |
| Hydrochloric Acid SCHEMBL2659325 | 0.96 | ALOX15 (0.32) | ALOX15RECQLTSHRTAS2R38 | |
| SCHEMBL19773677 | 0.86 | — | — | |
| SCHEMBL13866900 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL9487889 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4702017-A1 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2026-03-04 | — | — | EP | disclosed |
| EP-4695231-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Tenvie Therapeutics Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260008760-A1 | DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF | INSMED INCORPORATED | 2026-01-08 | — | — | US | disclosed |
| EP-4192831-B1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2025-10-22 | — | — | EP | disclosed |
| WO-2025064683-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20250091989-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-20 | — | — | US | disclosed |
| WO-2025034613-A1 | 3H-IMIDAZO[4,5-B]PYRIDINE COMPOUNDS AS NON-COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| US-20250034122-A1 | SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2025-01-30 | — | — | US | disclosed |
| WO-2024216209-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NICO THERAPEUTICS, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| EP-4441044-A1 | SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2024-10-09 | — | — | EP | disclosed |
| US-20020052395-A1 | Diphenyl ether compounds useful in therapy | ANDREWS MARK DAVID (GB) | 2002-05-02 | — | — | US | disclosed |
| WO-2001062726-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2001-08-30 | — | — | WO | disclosed |
| US-6228847-B1 | ADMINISTERING PYRROLO(3,2-D)PYRIMIDINE DERIVATIVES AS PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITOR | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2001-05-08 | — | — | US | disclosed |
| EP-1023308-A1 | INHIBITORS OF NUCLEOSIDE METABOLISM | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2000-08-02 | — | — | EP | disclosed |
| US-6066722-A | Inhibitors of nucleoside metabolism | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2000-05-23 | — | — | US | disclosed |
| US-5985848-A | EFFECTIVE INHIBITORS OF PURINE NUCLEOSIDE PHOSPHORYLASE AND/OR NUCLEOSIDE HYDROLASES; TREATMENT AND/OR PROPHYLAXIS OF A PROTOZOAN INFECTION | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 1999-11-16 | — | — | US | disclosed |
| WO-1999019338-A1 | INHIBITORS OF NUCLEOSIDE METABOLISM | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 1999-04-22 | — | — | WO | disclosed |
| EP-0056577-B1 | TRIAZOLYL-COUMARIN DERIVATIVES, THEIR PREPARATION AND USE AS OPTICAL BRIGHTENING AGENTS SCINTILLATORS AND DYESTUFFS FOR LASERS | BAYER AG (DE) | 1984-12-19 | — | — | EP | disclosed |
| US-4426530-A | Triazolylcoumarin compounds, and their preparation and use as optical brighteners, scintillators and laser dyestuffs | BAYER AKTIENGESELLSCHAFT (DE) | 1984-01-17 | — | — | US | disclosed |
| EP-0056577-A1 | Triazolyl-coumarin derivatives, their preparation and use as optical brightening agents scintillators and dyestuffs for lasers | BAYER AG (DE) | 1982-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091989-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, NRAS | ALOX15 2581/4885RECQL 910/4885TSHR 3881/4885 |
| US-20250034122-A1 | SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | USP30, USP47, USP1 | ALOX15 4202/4885RECQL 1473/4885TSHR 4463/4885 |
| US-20260008760-A1 | DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF | DPP9, DPP7, DPP4 | ALOX15 2760/4885RECQL 3600/4885TSHR 1159/4885 |
| US-20020052395-A1 | Diphenyl ether compounds useful in therapy | CBR1, OGFR, CBR3 | ALOX15 3629/4885RECQL 1380/4885TSHR 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.